Novo Nordisk Falls, Praxis Precision Rallies, Lululemon Rises | Stock Movers

On this episode of Stock Movers:

- Novo Nordisk (NVO) cut the price of its obesity drug Wegovy in China as the Danish drugmaker gears up for a potential flood of copycats. The reduction will “help alleviate the treatment burden for patients and improve their quality of life,” a spokesperson said by email. The list prices for the two highest dosages of Wegovy were cut by half in some Chinese provinces, local media Yicai reported on Monday, citing drug-procurement documents for southwestern Chinese provinces Yunnan and Sichuan. Shares of Novo Nordisk slipped.

- Praxis Precision (PRAX) rose after getting breakthrough therapy designation by FDA for its medication ulixacaltamide, which treats patients with essential tremor.

- Lululemon (LULU) founder Chip Wilson is pushing for changes to the board before the yogawear company selects a new chief executive officer. Wilson, one of Lululemon’s largest shareholders, nominated three director candidates for election at the 2026 annual meeting: former On Holding co-CEO Marc Maurer, former ESPN Chief Marketing Officer Laura Gentile and former Activision CEO Eric Hirshberg. Lululemon is unlikely to reach its goal to double sales to $12.5 billion in 2026 even with a lead over its activewear peers, according to a note from Poonam Goyal, senior analyst at Bloomberg Intelligence.

See omnystudio.com/listener () for privacy information.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Check out more episodes of Stock Movers

Follow Bloomberg Podcasts on Twitter

Visit our other YouTube channels:

Bloomberg Television

Bloomberg Originals

For coverage on news, markets and more

#Stocks #Markets #Finance #Investing #Podcast #Bloomberg

Novo Nordisk Falls, Praxis Precision Rallies, Lululemon Rises